Pharma & Bio
Technology
CEO of Shangya Bio, a Partner of Xcell Therapeutics Inc.: “China’s Recombinant Collagen Skin Boosters Reach the ‘J’ Level… Changes Are Coming to Korea, Too”
“The center of gravity in China’s medical beauty market is already shifting from hyaluronic acid (HA) to recombinant collagen. I believe the same shift will begin in South Korea as well.”Liu Yang, Gen…
- 2026-08-28 11:02:02
- Kim Seung-kwon
Technology
[PharmaResearch Deep Dive ②] Growth Rates for Rejuran and Others Plunge from 93.5% to 6.2%... Monopoly Premium at Risk of Disappearing
PharmaResearch(214450) The growth rate of domestic sales of medical devices (including Rejuran and Conjuran) plummeted from 93.5% to 6.2% for the first time in five quarters. The industry views this a…
- 2026-08-28 09:16:02
- Kim Seung-kwon
Lifestyle
[Exclusive] Ingenia Claims to Have Secured a Long-Term Shareholding Commitment from FI… Will Overhang Concerns Ease?
“Key executives at Ingenia Therapeutics recently met with major financial investors (FIs), including Intervest and Aurum Asset Management, and secured commitments to hold their stakes in the company f…
- 2026-08-28 08:46:02
- YU JIN-HEE
Lifestyle
OscoTech Integrates Struggling Subsidiary Genosco… Shareholders and Board Face Complex Calculations
It has been about six months since Oskotec announced its plan to make its subsidiary Genosco a wholly-owned subsidiary, but key preliminary procedures—such as the establishment of a special committee …
- 2026-08-28 08:31:02
- Kim Jinsoo
Technology
SK Biopharm Rallies on Opakalim Bet; Xcell Hits Intraday Upper Limit [K-Bio Pulse]
On Aug. 26, SK Biopharmaceuticals jumped 8.53% after announcing a licensing deal worth up to $795 million for its late-stage epilepsy drug candidate Opakalim, regaining the 90,000-won level following …
- 2026-08-28 08:05:04
- KIM SAE-MI
Technology
SK BIOPHARMACEUTICALS Soars 8% on 1.1 Trillion Won New Drug Deal… Xcell Therapeutics Inc. Hits Intraday High [Bio Spotlight]
On the 26th, buying interest surged in the biotech and healthcare sector, driven by companies seeking new growth engines. SK BIOPHARMACEUTICALS(326030)saw its stock price—which had recently been under…
- 2026-08-28 08:04:02
- KIM SAE-MI
Technology
Rejuran Injected into My Face—Still Not Approved in the U.S.?
PharmaResearch(214450)is seeking U.S. Food and Drug Administration (FDA) medical device approval for its flagship product, “Rejuran,” but is expected to face significant hurdles before actually enteri…
- 2026-08-27 09:51:01
- KIM SAE-MI
Technology
Seegene Inc., Whose 70% of Revenue Came from COVID-19 and Respiratory Diseases… Reduces ‘Winter Dependency’ Through GI and HPV Tests
Seegene ( Seegene Inc.(096530)), whose revenue was heavily concentrated in respiratory diagnostics during the COVID-19 pandemic, is now cultivating non-respiratory products—such as gastrointestinal (G…
- 2026-08-27 08:32:02
- NA EUN-KYUNG
Technology
Kim Nam-yong, CEO of Curiox: "More Order Contracts and Advance Payment Agreements with Global Companies Are Expected"
“We recently secured an equipment order worth 510 million won from a global pharmaceutical company in the cell and gene therapy (CGT) sector. We are currently in active discussions with more than 10 g…
- 2026-08-27 08:31:02
- Kim Seung-kwon
Lifestyle
Sillajen Hits Upper Limit on FDA Orphan Drug Designation, Hanmi Pharma Plunges [K-Bio Pulse]
While South Korea’s pharmaceutical and biotech sector traded lower across the board, Sillajen stood out by hitting the daily upper price limit. In contrast, Hanmi Pharmaceutical and Hanmi Science, whi…
- 2026-08-27 08:07:03
- SONG YOUNG-DOO
PHARM EDAILY
Shorts